Patient characteristics
| Characteristics . | N = 31 . |
|---|---|
| Age, median (range), y | 76 (18-87) |
| <80, n (%) | 23 (74) |
| ≥80, n (%) | 8 (26) |
| Sex, n (%) | |
| Female | 19 (61) |
| Male | 12 (39) |
| Race, n (%) | |
| White | 23 (74) |
| Asian | 5 (16) |
| Black | 1 (3) |
| Hispanic | 1 (3) |
| Not available | 1 (3) |
| Diagnosis, n (%) | |
| DLBCL, NOS | 22 (71) |
| High-grade BCL | 5 (16) |
| Intravascular LBCL | 2 (6) |
| Primary mediastinal large BCL | 1 (3) |
| TCHR LBCL | 1 (3) |
| Transformed disease, n (%) | |
| No | 24 (77) |
| Yes | 7 (23) |
| No. of prior lines, median (range) | 2 (2-7) |
| 2, n (%) | 19 (61) |
| 3, n (%) | 8 (26) |
| 4, n (%) | 3 (10) |
| 7, n (%) | 1 (3) |
| CNS disease at treatment with glofitamab, n (%) | |
| No | 27 (87) |
| Yes | 4 (13) |
| LDH, median (range) | 281 (112-8019) |
| Elevated LDH (>210 U/L) , n (%) | |
| No | 8 (26) |
| Yes | 23 (74) |
| Stage at glofitamab initiation, n (%) | |
| 1 | 1 (3) |
| 1E | 1 (3) |
| 2 | 0 (0) |
| 3 | 4 (13) |
| 4 | 25 (81) |
| Prior CAR T-cells, n (%) | |
| No | 6 (19) |
| Yes | 25 (81) |
| Refractory to CAR T-cells | |
| No | 14/25 (45) |
| Yes | 11/25 (35) |
| Before ASCT, n (%) | |
| No | 30 (97) |
| Yes | 1 (3) |
| Characteristics . | N = 31 . |
|---|---|
| Age, median (range), y | 76 (18-87) |
| <80, n (%) | 23 (74) |
| ≥80, n (%) | 8 (26) |
| Sex, n (%) | |
| Female | 19 (61) |
| Male | 12 (39) |
| Race, n (%) | |
| White | 23 (74) |
| Asian | 5 (16) |
| Black | 1 (3) |
| Hispanic | 1 (3) |
| Not available | 1 (3) |
| Diagnosis, n (%) | |
| DLBCL, NOS | 22 (71) |
| High-grade BCL | 5 (16) |
| Intravascular LBCL | 2 (6) |
| Primary mediastinal large BCL | 1 (3) |
| TCHR LBCL | 1 (3) |
| Transformed disease, n (%) | |
| No | 24 (77) |
| Yes | 7 (23) |
| No. of prior lines, median (range) | 2 (2-7) |
| 2, n (%) | 19 (61) |
| 3, n (%) | 8 (26) |
| 4, n (%) | 3 (10) |
| 7, n (%) | 1 (3) |
| CNS disease at treatment with glofitamab, n (%) | |
| No | 27 (87) |
| Yes | 4 (13) |
| LDH, median (range) | 281 (112-8019) |
| Elevated LDH (>210 U/L) , n (%) | |
| No | 8 (26) |
| Yes | 23 (74) |
| Stage at glofitamab initiation, n (%) | |
| 1 | 1 (3) |
| 1E | 1 (3) |
| 2 | 0 (0) |
| 3 | 4 (13) |
| 4 | 25 (81) |
| Prior CAR T-cells, n (%) | |
| No | 6 (19) |
| Yes | 25 (81) |
| Refractory to CAR T-cells | |
| No | 14/25 (45) |
| Yes | 11/25 (35) |
| Before ASCT, n (%) | |
| No | 30 (97) |
| Yes | 1 (3) |
ASCT, autologous stem cell transplant; DLBCL, diffuse large B-cell lymphoma; NOS, not otherwise specified; TCHR LBCL, T-cell histiocyte-rich LBCL.